Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 15, 2009, Pages 4097-4101

  Edmondson, Scott D ^a   Mastracchio, Anthony ^a   Cox, Jason M ^a   Eiermann, George J ^a   He, Huaibing ^a   Lyons, Kathryn A ^a   Patel, Reshma A ^a   Patel, Sangita B ^a   Petrov, Aleksandr ^a   Scapin, Giovanna ^a   Wu, Joseph K ^a   Xu, Shiyao ^a   Zhu, Bing ^a   Thornberry, Nancy A ^a   Roy, Ranabir Sinha ^a   Weber, Ann E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Benzimidazole; Buchwald coupling; Dipeptidyl peptidase 8; Dipeptidyl peptidase IV; DPP 4; DPP 8; DPP 9; DPP IV; GLP 1; Glucagon like peptide 1; Imidazopyridine; QPP; Quiescient peptidyl peptidase; Sitagliptin

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; IMIDAZOPYRIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; RAT;

ANIMALS; BENZIMIDAZOLES; CHEMISTRY, PHARMACEUTICAL; CRYSTALLOGRAPHY, X-RAY; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOGS; DRUG DESIGN; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYDROLYSIS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; MACACA MULATTA; MICE; PIPERIDINES; PYRAZINES; PYRIDINES; RATS; TRIAZOLES;

EID: 67650002790     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.06.011     Document Type: Article

References (26)

1. Karasik A., Aschner P., Katzeff H., Davies M.J., and Stein P.P. Curr. Med. Res. Opin. 24 (2008) 489
2. Thornberry N.A., and Weber A.E. Curr. Top. Med. Chem. 7 (2007) 557-568
3. ™ (Sitagliptin). In: Antitargets Vaz R.J., and Klabunde T. (Eds). Methods and Principles in Medicinal Chemistry Vol. 38 (2008), Wiley-VCH 401-422
4. For lead DPP-4 references, see:. Havale S.H., and Pal M. Bioorg. Med. Chem. 17 (2009) 1783
5. Pei Z. Curr. Opin. Drug Disc. Dev. 11 (2008) 512
6. Ahren B. Exp. Opin. Emerg. Drugs 13 (2008) 593
7. Idris I., and Donnelly R. Diab. Obes. Metab. 9 (2007) 153
8. For lead GLP-1 references, see. Holst J.J., Vilsboll T., and Deacon C.F. Mol. Cell. Endocrinol. 297 (2009) 127
9. Kim W., and Egan J.M. Pharm. Rev. 60 (2008) 470
10. Holst J.J. Physiol. Rev. 87 (2007) 1409
11. During M.J., Cao L., Zuzga D.S., Francis J.S., Fitzsimons H.L., Jiao X., Bland R.J., Klugmann M., Banks W.A., Drucker D.J., and Haile C.N. Nat. Med. 9 (2003) 1173
12. Biftu T., Scapin G., Singh S., Feng D., Becker J.W., Eiermann G., He H., Lyons K., Patel S., Petrov A., Sinha-Roy R., Zhang B., Wu J., Zhang X., Doss G.A., Thornberry N.A., and Weber A.E. Bioorg. Med. Chem. Lett. 17 (2007) 3384
13. Gao Y.-D., Feng D., Sheridan R.P., Scapin G., Patel S.B., Wu J.K., Shang J., Sinha-Roy R., Thornberry N.A., Weber A.E., and Biftu T. Bioorg. Med. Chem. Lett. 17 (2007) 3877
14. Cox J.M., Harper B., Mastracchio A., Leiting B., Sinha Roy R., Patel R.A., Wu J.K., Lyons K.A., He H., Xu S., Zhu B., Thornberry N.A., Weber A.E., and Edmondson S.D. Bioorg. Med. Chem. Lett. 17 (2007) 4579
15. 1H NMR and LC-MS. Detailed procedures and spectral data for selected compounds are described in the following patents: Cox, J. M.; Edmondson, S. D.; Mastracchio, A. Fused Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes WO 2006/058064, filed Nov. 22, 2005.
16. Cox, J. M.; Edmondson, S. D.; Mastracchio, A. Fused Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes WO 2007/024993, filed Aug. 22, 2006; Biftu, T.; Cox, J. M.; Edmondson, S. D.; Mastracchio, A. Fused Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes WO 2007/070434, filed Dec. 8, 2006.
17. Klapars A., Huang X., and Buchwald S.L. J. Am. Chem. Soc. 124 (2002) 7421
18. 50 determinations for DPP-4 and QPP were carried out as described in. Leiting B., Pryor K.D., Wu J.K., Marsilio F., Patel R.A., Craik C.S., Ellman J.A., Cummings R.T., and Thornberry N.A. Biochem. J. 371 (2003) 525
19. 50's are an average of n ≥ 4, with standard deviations less than 60% of the average.
20. For a discussion of the relevance of selectivity over DPP-8 and DPP-9, see. Lankas G.R., Leiting B., Sinha Roy R., Eiermann G.J., Beconi M.G., Biftu T., Chan C.-C., Edmondson S., Feeney W.P., He H., Ippolito D.E., Kim D., Lyons K.A., Ok H.O., Patel R.A., Petrov A.N., Pryor K.A., Qian X., Reigle L., Woods A., Wu J.K., Zaller D., Zhang X., Zhu L., Weber A.E., and Thornberry N.A. Diabetes 54 (2005) 2988
21. The atomic coordinates for the X-ray structures of DPP-4 in complex with 25 and 34 have been deposited into the RCSB protein data bank under RCSB ID codes RCSB052890 and RCSB052891, and under PDB ID codes 3HAB and 3HAC, respectively.
22. 50 determinations for hERG was carried out as described in. Friesen R.W., Ducharme Y., Ball R.G., Blouin M., Boulet L., Cote B., Frenette R., Girard M., Guay D., Huang Z., Jones T.R., Laliberte F., Lynch J.J., Mancini J., Martins E., Masson P., Muise E., Pon D.J., Siegel P.K.S., Styhler A., Tsou N.N., Turner M.J., Young R.N., and Girard Y. J. Med. Chem. 46 (2003) 2017
23. Edmondson S.D., Mastracchio A., Mathvink R.J., He J., Harper B., Park J.-J., Beconi M., Di Salvo J., Eiermann G.J., He H., Leiting B., Leone J.F., Levorse D.A., Lyons K., Patel R.A., Patel S.B., Petrov A., Scapin G., Shang J., Sinha Roy R., Smith A., Wu J.K., Xu S., Zhu B., Thornberry N.A., and Weber A.E. J. Med. Chem. 49 (2006) 3614
24. 50 determinations for rabbit calcium channel were carried out as described in. Shoemaker H., Hicks P., and Langer S. J. Cardiovasc. Pharm. 9 (1987) 173
25. Rendic S. Drug. Metab. Rev. 34 (2002) 83
26. Marquet D., Baggio L., Kobayashi T., Bernard A.-M., Pierres M., Nielsen M., Ribel U., Watanabe T., Drucker D.J., and Wagtmann N.P. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 6874